Mirtazapine

Generic Name
Mirtazapine
Brand Names
Remeron
Drug Type
Small Molecule
Chemical Formula
C17H19N3
CAS Number
85650-52-8
Unique Ingredient Identifier
A051Q2099Q
Background

Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...

Indication

This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...

Associated Conditions
Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Associated Therapies
-

Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2011-11-06
Last Posted Date
2020-03-20
Lead Sponsor
Seoul National University Boramae Hospital
Target Recruit Count
5
Registration Number
NCT01465919
Locations
🇰🇷

SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of

Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-10-25
Last Posted Date
2017-08-31
Lead Sponsor
Capital Medical University
Target Recruit Count
525
Registration Number
NCT01458626
Locations
🇨🇳

Beijing Anding Hospital, Beijing, Beijing, China

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-02-24
Last Posted Date
2018-11-07
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT01302964
Locations
🇺🇸

Riley Child and Adolescent Psychiatry Clinic Riley Hospital, Indianapolis, Indiana, United States

🇺🇸

Lurie Center -MassGeneral Hospital, Lexington, Massachusetts, United States

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

First Posted Date
2010-12-20
Last Posted Date
2016-08-02
Lead Sponsor
Capital Medical University
Target Recruit Count
333
Registration Number
NCT01263080
Locations
🇨🇳

Beijing Anding Hospital, Capital Medical University, Beijing, Beijing, China

Mirtazapine Versus Placebo in Functional Dyspepsia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-11-15
Last Posted Date
2024-07-01
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
35
Registration Number
NCT01240096
Locations
🇧🇪

University Hospitals, Leuven, Vlaanderen, Belgium

Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

First Posted Date
2010-08-10
Last Posted Date
2016-04-08
Lead Sponsor
Research Foundation for Mental Hygiene, Inc.
Target Recruit Count
38
Registration Number
NCT01178671
Locations
🇺🇸

Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

First Posted Date
2010-07-20
Last Posted Date
2018-04-09
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
20
Registration Number
NCT01165541
Locations
🇺🇸

Dartmouth Medical School Department of Psychiatry's Addition Research Center, Bedford, New Hampshire, United States

🇺🇸

Dartmouth Medical School Department of Psychiatry's Addiction Research Center, Hanover, New Hampshire, United States

Strategic Use of New Generation Antidepressants for Depression

First Posted Date
2010-04-23
Last Posted Date
2016-10-03
Lead Sponsor
Kyoto University
Target Recruit Count
2011
Registration Number
NCT01109693
Locations
🇯🇵

Nagoya City University Hospital, Nagoya, Aichi, Japan

🇯🇵

Kochi Medical School Hospital, Nangoku, Kochi, Japan

Pharmacogenetic Study of Mirtazapine Response in Depressed Patients

Not Applicable
Conditions
Interventions
First Posted Date
2009-12-25
Last Posted Date
2015-12-31
Lead Sponsor
Samsung Medical Center
Target Recruit Count
100
Registration Number
NCT01039740
Locations
🇰🇷

Samsung Medical Center, Kangnam, Seoul, Korea, Republic of

Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-08-18
Last Posted Date
2009-08-18
Lead Sponsor
Universidad Nacional de Rosario
Target Recruit Count
40
Registration Number
NCT00960830
Locations
🇦🇷

Cl Sn Nicol, San Nicolas, Bs As, Argentina

© Copyright 2024. All Rights Reserved by MedPath